
Opinion|Videos|May 16, 2025
Impact of CHE on Patient Quality of Life
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how chronic hand eczema (CHE) significantly impacts patients' daily activities and work productivity, as painful symptoms and limitations make routine tasks challenging, while avoidance recommendations are often difficult to implement.
Advertisement
Video content above is prompted by the following:
Patient Impact of CHE
Key Themes:
- Functional limitations: Significant impairment in basic daily activities and professional responsibilities.
- Work productivity: Both presenteeism and absenteeism affect patients' occupational performance.
- Treatment challenges: Difficulty implementing avoidance strategies when exposures are occupationally necessary.
Notable Insights:
Dr Chovatiya described the cycle that patients experience: "Traditional medications, half-hearted avoidance behavior, or impossible-to-follow recommendations for avoidance behavior," highlighting the practical challenges patients face.
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
SUMMIT Substudy Reveals Tirzepatide’s Impact on LV, Atrial Metrics of HFpEF
5

